| 1 | 22407832 | Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. | Clin Cancer Res | 2012 May 1 |
5 |
| 2 | 23085766 | Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. | Breast Cancer Res Treat | 2012 Dec |
5 |
| 3 | 23090679 | Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. | Leukemia | 2013 Mar |
4 |
| 4 | 23386687 | Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. | Mol Cancer Res | 2013 May |
4 |
| 5 | 23828865 | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. | Endocr Relat Cancer | 2013 Oct |
3 |
| 6 | 24198241 | The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. | Clin Cancer Res | 2014 Jan 1 |
5 |
| 7 | 24243565 | Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. | Int J Cancer | 2014 May 15 |
2 |
| 8 | 24286145 | Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. | J Neurosurg | 2014 Feb |
4 |
| 9 | 24385238 | The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW 264.7 cells. | Inflammation | 2014 Jun |
4 |
| 10 | 24562770 | mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. | Breast Cancer Res Treat | 2014 Apr |
8 |
| 11 | 24623675 | Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2014 Aug |
2 |
| 12 | 25100829 | Epstein-Barr virus-encoded latent membrane protein 2A promotes the epithelial-mesenchymal transition in nasopharyngeal carcinoma via metastatic tumor antigen 1 and mechanistic target of rapamycin signaling induction. | J Virol | 2014 Oct |
3 |
| 13 | 25156912 | GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro. | Mol Carcinog | 2015 Nov |
1 |
| 14 | 25162417 | A critical role for the mTORC2 pathway in lung fibrosis. | PLoS One | 2014 |
5 |
| 15 | 25261369 | Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. | Oncotarget | 2014 Sep 30 |
3 |
| 16 | 25425103 | mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. | Apoptosis | 2015 Jan |
3 |
| 17 | 25519700 | MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. | Mol Cancer Ther | 2015 Feb |
8 |
| 18 | 25591719 | Augmented pentose phosphate pathway plays critical roles in colorectal carcinomas. | Oncology | 2015 |
2 |
| 19 | 25692620 | The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. | Cancer Biol Ther | 2015 |
5 |
| 20 | 25849580 | Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma. | Cell Commun Signal | 2015 Mar 1 |
4 |
| 21 | 25893295 | Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. | Oncogene | 2016 Feb 4 |
4 |
| 22 | 25990456 | Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo. | Tumour Biol | 2015 Sep |
2 |
| 23 | 26170311 | Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. | Proc Natl Acad Sci U S A | 2015 Jul 28 |
1 |
| 24 | 26427479 | The mTOR Kinase Inhibitor INK128 Blunts Migration of Cultured Retinal Pigment Epithelial Cells. | Adv Exp Med Biol | 2016 |
4 |
| 25 | 26452980 | Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. | Haematologica | 2015 Dec |
16 |
| 26 | 26514724 | Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma. | Biochem Biophys Res Commun | 2015 Dec 4-11 |
1 |
| 27 | 26536665 | Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth. | Oncotarget | 2016 Feb 9 |
3 |
| 28 | 26574479 | Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers. | Cancer Res | 2015 Nov 15 |
9 |
| 29 | 26800393 | TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. | Am J Hematol | 2016 Jun |
2 |
| 30 | 27391151 | MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. | Oncotarget | 2016 Aug 23 |
4 |
| 31 | 27574017 | The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7. | Int J Oncol | 2016 Sep |
2 |
| 32 | 27577794 | Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma. | Cancer Discov | 2016 Oct |
1 |
| 33 | 27812353 | INK128 Exhibits Synergy with Azoles against <i>Exophiala</i> spp. and <i>Fusarium</i> spp. | Front Microbiol | 2016 |
2 |
| 34 | 27863413 | RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. | Oncotarget | 2017 Jan 24 |
1 |
| 35 | 28450157 | The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. | Cancer Lett | 2017 Aug 1 |
2 |
| 36 | 28482026 | Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. | Neuro Oncol | 2017 Nov 29 |
1 |
| 37 | 28574664 | Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma. | Cancer Sci | 2017 Aug |
1 |
| 38 | 28582547 | The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. | Neuro Oncol | 2017 Oct 1 |
3 |
| 39 | 28601972 | TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. | Cancer Chemother Pharmacol | 2017 Aug |
3 |
| 40 | 28733220 | Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. | J Hepatol | 2017 Dec |
5 |
| 41 | 29079660 | Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR<sup>+</sup>/HER2<sup>+</sup> Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. | Clin Cancer Res | 2018 Jan 15 |
2 |
| 42 | 29088718 | Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development. | Oncotarget | 2017 Sep 26 |
1 |
| 43 | 29133622 | Ceritinib Enhances the Efficacy of Trametinib in <i>BRAF/NRAS</i>-Wild-Type Melanoma Cell Lines. | Mol Cancer Ther | 2018 Jan |
3 |
| 44 | 29464110 | Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. | ESMO Open | 2018 |
3 |
| 45 | 29508246 | A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. | Invest New Drugs | 2018 Jun |
8 |
| 46 | 29623577 | Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. | Breast Cancer Res Treat | 2018 Aug |
2 |
| 47 | 29899840 | CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. | Oncotarget | 2018 May 25 |
5 |
| 48 | 30060081 | mTOR regulates NLRP3 inflammasome activation via reactive oxygen species in murine lupus. | Acta Biochim Biophys Sin (Shanghai) | 2018 Sep 1 |
6 |
| 49 | 30080208 | Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer. | J Vis Exp | 2018 Jul 21 |
3 |
| 50 | 30084835 | Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. | Clin Cancer Res | 2019 Jan 1 |
4 |